Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06400550 · ClinicalTrials.gov registry record
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
A clinical trial of Melanoma (Skin), sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT06400550: Recruiting study of Melanoma (Skin), sponsored by University of Texas Southwestern Medical Center.
NCT06400550 is a study of Melanoma (Skin) that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 400 participants, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (223% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06400550, a study of Melanoma (Skin), is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to observe metabolic features associated with human melanoma tumors.
Primary Outcome
In patients receiving a \[U-13C\]Glucose infusion, assess glucose utilization in the TCA cycle by melanoma tumors (defined as fractional enrichment of 13C-label in TCA metabolites)
Conditions Studied
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2028-08-01 |
What NCT06400550 shows while recruiting
NCT06400550 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (223% higher).
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 0 interventions.
NCT06400550 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06400550 about?
NCT06400550 is a clinical study titled "Identification of Metabolic Phenotypes Associated With Melanoma Metastasis". The goal of this study is to observe metabolic features associated with human melanoma tumors.
What is the current status of trial NCT06400550?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2018-08-01. Estimated completion is 2028-08-01.
What conditions does trial NCT06400550 study?
This clinical trial studies the following conditions: Melanoma (Skin).
Who is sponsoring clinical trial NCT06400550?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06400550 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06400550's enrollment target sits among peer trials
400 3rd of 30 higher than 28 of 30 other Melanoma (Skin) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
RECRUITING · Phase 1
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
DermaSensor Postmarket Surveillance Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI